Author: Egerup, P.; Olsen, L. F.; Christiansen, A.-M. H.; Westergaard, D.; Severinsen, E. R.; Hviid, K. V. R.; Kolte, A. M.; Boje, A. D.; Bertelsen, M.-L. M. F.; Praetorius, L.; Zedeler, A.; Nielsen, J. R.; Bang, D.; Berntsen, S.; Ethelberg-Findsen, J.; Storm, D. M.; Bello-Rodriguez, J.; Ingham, A.; Olle-Lopez, J.; Hoffmann, E.; Wilken-Jensen, C.; Krebs, L.; Joergensen, F. S.; Westh, H. T.; Jorgensen, H. L.; la Cour Freiesleben, N.; Nielsen, H. S.
Title: Impact of SARS-CoV-2 antibodies at delivery in women, partners and newborns Cord-id: pi1hf6xg Document date: 2020_9_15
ID: pi1hf6xg
Snippet: Background: Only few studies have focused on serological testing for SARS-CoV-2 in pregnant women and no previous study has investigated the frequency in partners. The aim was to investigate the frequency and impact of SARS-CoV-2 in parturient women, their partners and newborns. Methods: From April 4th to July 3rd, 2020, all parturient women, their partners and newborns were invited to participate in the study. Participating women and partners had a pharyngeal swab and a blood sample taken at ad
Document: Background: Only few studies have focused on serological testing for SARS-CoV-2 in pregnant women and no previous study has investigated the frequency in partners. The aim was to investigate the frequency and impact of SARS-CoV-2 in parturient women, their partners and newborns. Methods: From April 4th to July 3rd, 2020, all parturient women, their partners and newborns were invited to participate in the study. Participating women and partners had a pharyngeal swab and a blood sample taken at admission and immediately after delivery a blood sample was drawn from the umbilical cord. The swabs were analyzed for SARS-CoV-2 RNA by PCR and the blood samples were analyzed for SARS-CoV-2 antibodies. Full medical history, obstetric- and neonatal information were available. Results: A total of 1,361 parturient women, 1,236 partners and 1,342 newborns participated in the study. No associations between previous COVID-19 disease and obstetric- or neonatal complications were found. The adjusted serological prevalence was 2.9% in women and 3.8% in partners. The frequency of blood type A was significantly higher in women with antibodies compared to women without antibodies. 17 newborns had SARS-CoV-2 IgG antibodies, and none had IgM antibodies. Full serological data from 1,052 families showed an absolute risk of infection of 0.37 if the partner had antibodies. Only 55% of individuals with antibodies reported symptoms. Conclusion: This large prospective cohort study reports no association between COVID-19 and obstetric- or neonatal complications. The family pattern showed a substantial increase in absolute risk for women living with a partner with antibodies.
Search related documents:
Co phrase search for related documents- absolute risk and acute disease: 1, 2, 3, 4, 5, 6
- absolute risk and additional study: 1
- absolute risk and adjusted prevalence: 1, 2
- absolute risk and low prevalence: 1
- absolute risk and lung disease: 1, 2, 3
- acute disease and additional study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute disease and adjust prevalence: 1
- acute disease and low prevalence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- acute disease and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute disease and lung disease smoking: 1, 2, 3
- additional study and low prevalence: 1, 2
- additional study and lung disease: 1, 2, 3, 4
- adjusted prevalence and low prevalence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- adjusted prevalence and lung disease: 1
- low prevalence and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
Co phrase search for related documents, hyperlinks ordered by date